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The  BEEHIVE  (Bridging  the Evolution  and  Epidemiology  of  HIV  in  Europe)  project  aims  to analyse  nearly-
complete  viral  genomes  from  >3000 HIV-1  infected  Europeans  using  high-throughput  deep  sequencing
techniques  to  investigate  the  virus  genetic  contribution  to virulence.  Following  the development  of  a
computational  pipeline,  including  a new  de  novo  assembler  for RNA  virus  genomes,  to  generate  larger
contiguous  sequences  (contigs)  from  the abundance  of  short  sequence  reads  that  characterise  the  data,
another area  that  determines  genome  sequencing  success  is the  quality  and  quantity  of the  input  RNA.  A
pilot experiment  with  125  patient  plasma  samples  was performed  to  investigate  the  optimal  method  for
isolation of  HIV-1  viral  RNA  for  long  amplicon  genome  sequencing.  Manual  isolation  with  the  QIAamp
Viral  RNA  Mini  Kit  (Qiagen)  was  superior  over  robotically  extracted  RNA  using  either  the  QIAcube  robotic
system,  the  mSample  Preparation  Systems  RNA  kit  with  automated  extraction  by  the  m2000sp  system
(Abbott  Molecular),  or the  MagNA  Pure  96  System  in  combination  with  the  MagNA  Pure  96  Instrument
(Roche  Diagnostics).  We  scored  ampliﬁcation  of  a set  of four HIV-1  amplicons  of ∼1.9, 3.6, 3.0 and  3.5 kb,
and  subsequent  recovery  of near-complete  viral  genomes.
Subsequently,  616  BEEHIVE  patient  samples  were  analysed  to  determine  factors  that  inﬂuence  suc-
cessful  ampliﬁcation  of the genome  in  four overlapping  amplicons  using  the  QIAamp  Viral  RNA  Kit  for
viral  RNA  isolation.  Both  low  plasma  viral  load  and  high  sample  age  (stored  before  1999)  negatively  inﬂu-
enced the  ampliﬁcation  of  viral  amplicons  >3  kb.  A  plasma  viral  load  of  >100,000  copies/ml  resulted  in
successful  ampliﬁcation  of  all four  amplicons  for 86%  of the  samples,  this  value  dropped  to  only  46% for
samples  with  viral  loads  of <20,000  copies/ml.
© 2016  Elsevier  B.V.  All  rights  reserved.Please cite this article in press as: Cornelissen, M.,  et al., From clinical sa
of HIV-1 RNA for high-throughput deep sequencing. Virus Res. (2016)
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Enabled by the recent developments in high-throughput
sequencing techniques, the molecular analysis of complete ormple to complete genome: Comparing methods for the extraction
, http://dx.doi.org/10.1016/j.virusres.2016.08.004
nearly-complete viral genomes, including HIV, is now becom-
ing the new research standard. Complete genomes contain more
information on e.g. viral virulence elements than the shorter
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enome fragments that were previously investigated using Sanger
ideoxynucleotide chain terminator sequencing methods. How-
ver, assembly of complete viral genomes from the relatively short
eads generated by most high-throughput sequencing systems has
roven to be a challenge, and much effort has been directed towards
ptimization of this part of the process. The computational tools to
rocess high-throughput sequencing data are now coming of age,
o that it is now time to critically examine earlier steps in the pro-
ess. Many experimental steps have to be performed between the
solation of nucleic acids from a patient sample and the investiga-
ion of the assembled HIV-1 genomes. Many of these are potentially
xecuted under suboptimal conditions that need to be improved.
everal factors have to be taken into account, including sample
torage, storage temperature, storage time, number of freeze-thaw
ycles, RNA/DNA extraction methods, and selection of the primers
s well as the enzymes for reverse transcription and PCR ampli-
cation. For RNA viruses, selection of the reverse-transcriptase
RT) enzyme and primers for the RT-reaction are major concerns.
or genetically variable viruses such as Human Immunodeﬁciency
irus type 1 (HIV-1) and Hepatitis C Virus (HCV), the primers
sed for subsequent DNA ampliﬁcation are also important. Within
n infected patient, diversiﬁcation of the virus population during
hronic infection increases the likelihood that primers designed
o amplify early virus variants may  not work optimally on sub-
equent variants. In addition, the plasma viral load that primarily
etermines the amount of starting material for the RT reaction can
iffer signiﬁcantly between patients. If the input material for high-
hroughput sequencing, the ampliﬁed cDNA/DNA, is of low yield
nd/or poor quality, it follows that investing time and money into
ptimising assembly of poor quality data is not cost effective and
lmost impossible in high-throughput settings.
The BEEHIVE (Bridging the Evolution and Epidemiology of HIV in
urope) project is a large scale study to determine the viral genetic
asis of HIV-1 virulence using genome high-throughput sequenc-
ng. The project aims to collect nearly-complete viral genomes
rom >3000 HIV-1 infected European individuals who  are either
ecent seroconverters or have presented with an acute HIV infec-
ion, enabling an estimate of the duration of infection. Samples are
ollected from participating hospitals and institutes in six Euro-
ean countries. For each eligible patient, the ﬁrst set-point viral
oad sample has been retrieved. Viral RNA is extracted at a central
aboratory (AMC, Amsterdam, The Netherlands) and subsequently
equenced at the Wellcome Trust Sanger Institute (Hinxton, UK),
here the RNA is further processed. To investigate the effect of dif-
erent nucleic acid isolation methods, and manual versus robotic
xtraction, 125 samples were ﬁrst examined in ﬁve pilot exper-
ments. After identiﬁcation of the optimal isolation technique,
16 further BEEHIVE samples were analysed. Ampliﬁcation and
equencing results were compared to sample characteristics such
s age and the number of viral copies used as input material for the
T reaction. In addition, an overview of nucleic acid isolation meth-
ds used in literature for HIV-1 complete genome high-throughput
equencing will be provided.
. Materials and methods
.1. Patient material
Patients eligible for inclusion in the BEEHIVE study have to meet
he following criteria: (i) a known seroconversion interval of max-
mum one year between the last negative and the ﬁrst positivePlease cite this article in press as: Cornelissen, M.,  et al., From clinical sa
of HIV-1 RNA for high-throughput deep sequencing. Virus Res. (2016)
IV test or clear evidence of acute illness or recent HIV-1 infec-
ion at the ﬁrst positive test. (ii) Patients should be anti-retroviral
herapy (ART) naïve, i.e. have not taken therapy for the ﬁrst six
onths following the ﬁrst positive test. (iii) Patients should have PRESS
arch xxx (2016) xxx–xxx
at least one viral load determination, or a sample that can be used
for this purpose should be available, dating to 6–24 months after
the ﬁrst positive test and before the start of any ART. (iv) Lastly,
a sample of at least 500 l of frozen EDTA blood plasma or serum
taken between 0 and 24 months following the ﬁrst positive test
should be available, also before the start of any ART. Samples were
stored at −80 ◦C. The ﬁrst samples included in BEEHIVE were from
the Netherlands, where Stichting HIV Monitoring (SHM; HIV Mon-
itoring Foundation) acts as the national reference centre collecting
data from all HIV-positive individuals in care. In the Netherlands,
most HIV-1 positive samples meeting the above criteria are from
men  who have sex with men  (MSM)  that are mostly infected with
HIV-1 subtype B; in the 1980s 100% of MSM  were infected with
subtype B, in November 2011 this ﬁgure was reduced to 77% sub-
type B infections (Bezemer et al., 2015; van der Kuyl et al., 2013).
All HIV-1 RNA isolations for the BEEHIVE study were performed at
the Department of Medical Microbiology of the Academic Medical
Center in Amsterdam, the Netherlands.
2.2. HIV-1 RNA isolation methods
Viral RNA isolation methods tested in the pilot experiments
were the QIAamp Viral RNA Mini Kit that uses spin columns to
purify the RNA (Qiagen, Venlo, the Netherlands), the mSample
Preparation Systems RNA kit for sample preparation with auto-
mated extraction by the m2000sp system (Abbott Molecular, Des
Plaines, IL, USA), and the MagNA Pure 96 System in combination
with the MagNA Pure 96 Instrument (Roche Diagnostics Neder-
land, Almere, Netherlands). The QIAamp Viral RNA isolation was
done either manually or using the QIAcube robotic system, which is
designed for fully automated sample preparation with the QIAamp
RNA isolation kits. All RNA extractions were performed according
to the manufacturers’ instructions. For details of the isolation meth-
ods, see Supplementary Table 1. As input material, 200–250 l of
blood plasma or serum was used, regardless of the viral genome
copy number; for the automated extractions, the input volume was
1 ml.
2.3. Quality control of the isolated HIV-1 RNA
To assess the quality of the isolated viral RNA, 10 l (1/8) was
used in an RT-PCR using the SuperscriptIII One-step RT-PCR Sys-
tem with Platinum Taq DNA polymerase (Invitrogen) performed
according to the manufacturer’s instructions. Primers used were
5′ED31 5′-CCTCAGCCATTACACAGGCCTGTCCAAAG -3′ (Delwart
et al., 1995) and 3′A1191 (5′-AGCAATGTATGCCCCTCCCAT-3′, posi-
tion 7510-7531 of the HXB2 reference strain with GenBank
accession number K03455) which target the HIV-1 envelope gene
to generate a product of 725 base pairs (bp). PCR products were
analysed on a 2% agarose gel. The HIV-1 envelope product could be
ampliﬁed from 98.5% of the RNA samples. Samples that failed this
quality control were not used for subsequent complete genome RT-
PCR ampliﬁcation and are not included in the numbers reported in
this study.
2.4. RT-PCR ampliﬁcation and high-throughput sequencing of
nearly-complete HIV-1 genomes
Four 5 l aliquots of viral RNA were reverse transcribed and
ampliﬁed using the SuperScriptIII One-Step RT-PCR system with
Platinum Taq DNA High Fidelity polymerase (Invitrogen) using
four different primer sets (Gall et al., 2012). The pan-HIV-1 spe-mple to complete genome: Comparing methods for the extraction
, http://dx.doi.org/10.1016/j.virusres.2016.08.004
ciﬁc primer sets target semi-conserved regions of the genome and
were developed using an alignment of approximately 1500 HIV-
1 genome sequences (Gall et al., 2012). The primer sets amplify
four overlapping amplicons that span the entire protein-coding
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Table 1
Outcomes of the pilot experiment and ﬁve initial BEEHIVE sample sets.
Sample batch No. Viral loads (copies/ml) Year of isolation RNA extraction RT-PCR results (no. of amplicons)
0–2 3 4 Sequencing method Complete
HIV-1 genomes
No. % No. % No. % No. %
Pilot 1 45 12,572–2,800,000 1996–2010 QIAamp Viral RNA [manual] 0 0 5 11.1 40 88.9 Roche/454 38 84.4
Pilot  2 24 4037–1,079,658 2012 M2000 (Abbott) 24 100 0 0 0 0 N/A N/A N/A
Pilot  3aa 12 14,100–1,929,719 2012 M2000 (Abbott) 11 91.7 1 8.3 0 0 N/A N/A N/A
Pilot  3ba 12 14,100–1,929,719 2012 MagNa Pure (Roche) 9 75 1 8.3 2 16.7 N/A N/A N/A
Pilot  4 20 19,508–1,012,000 2012 MagNa Pure (Roche) 20 100 0 0 0 0 N/A N/A N/A
Pilot  5 12 13,514–173,219 2012 QIAcube + QIAamp Viral RNA 4 33.3 4 33.3 4 33.3 MiSeq 150 bp PE 4 33.3
Total  125
BEEHIVE 1 48 7566–1,744,469 1992–2009 QIAamp Viral RNA [manual] 4 8.3 9 18.8 35 72.9 MiSeq 150 bp PE 35 72.9
BEEHIVE  2b 103 4200–978,120 1999–2011 QIAamp Viral RNA [manual] 3 2.9 13 12.6 87 84.5 MiSeq 250 bp PE 76 73.8
BEEHIVE  3b 206 1160–1,012,000 1985–2011 QIAamp Viral RNA [manual] 59 28.6 49 23.8 98 47.6 MiSeq 300 bp PE 88 42.7
BEEHIVE  4b 159 40–2,730,000 1985–2011c QIAamp Viral RNA [manual] 2 1.3 15 9.4 142 89.3 MiSeq 300 bp PE 132 83
BEEHIVE  5b 100 40–3,681,880 1998–2011 QIAamp Viral RNA [manual] 9 9 9 9 82 82 MiSeq 300 bp PE 73 73
Total  616 77 12.5 95 15.4 444 72.1 404 65.6
N/A = not applicable.
a The same sample set was  used in pilot 3a and 3b.
b Pre-screened for RNA quality by env RT-PCR.
c One sample was  from 1985, the remaining samples were from 1999 or later.
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Fig. 1. RT-PCR success rate by BEEHIVE sample subset. Percentages of samples that
generated 0–2, 3, or 4 HIV-1 amplicons are presented for the ﬁve BEEHIVE pilot
experiments.
Fig. 2. RT-PCR success rate and sample age. The percentage of BEEHIVE samples thatARTICLEIRUS-96936; No. of Pages 7
 M. Cornelissen et al. / Viru
equence and almost the complete HIV-1 RNA genome. Ampli-
on pan-HIV-1 1 (5′LTR-gag) is approximately 1.9 kb, amplicon
an-HIV-1 2 (gag-pol) is 3.6 kb, amplicon pan-HIV-1 3 (pol-env) is
 kb, and amplicon pan-HIV-1 4 (tat-3′LTR) is 3.5 kb. For Roche/454
equencing, amplicons were pooled in equimolar amounts. Single-
tranded DNA libraries were prepared from 500 ng DNA with the
S FLX Titanium Rapid Library Preparation Kit according to the
anufacturer’s instructions, using one of the 12 Multiplex Iden-
iﬁer (MID) adaptors for each sample. Sequencing was performed
sing the Genome Sequencer FLX Instrument and GS FLX Titanium
eries reagents as described previously (Gall et al., 2012). For Illu-
ina sequencing, 5 l of amplicon I were pooled with 10 l each of
mplicons II–IV. Libraries were prepared from 50 to 1000 ng DNA
s described in Quail et al. (2008, 2012), using one of 96 multiplex
daptors for each sample. Paired-end sequencing was  performed
sing the Illumina MiSeq instrument as described previously (Gall
t al., 2014), with read lengths as outlined in Table 1.
.5. Virus genome assembly and determination of the HIV-1
ubtype
Assembly of HIV-1 genomes from Roche/454 data was per-
ormed as described previously (Gall et al., 2012), while the de novo
ssembler IVA (Iterative Virus Assembler, (Hunt et al., 2015)) was
sed for Illumina MiSeq data. A genome assembly was deﬁned as
nearly-complete” if (1) the contigs cover at least 96% of the ampli-
able genome, demarcated by the two outermost RT-PCR primers,
nd (2) read coverage was  present before or at the start of the gag
ene and reached the end of the nef gene. Subtyping was done using
OMET at the contig level (Struck et al., 2014). Samples resulting
n a single contig classiﬁed as “unassigned” by COMET, and sam-
les resulting in multiple contigs classiﬁed as different subtypes by
OMET, were categorised as “unassigned”.
.6. Overview of HIV-1 RNA isolation methods used in the
iterature
A survey of HIV-1 RNA isolation methods for high-throughput
equencing was performed using the PubMed database at www.
cbi.nlm.nih.gov/pubmed with the search terms HIV-1; RNA
solation; complete genome; clinical samples; next-generation
equencing, high-throughput sequencing; Illumina MiSeq; Roche
54; PacBio; Ion Torrent, in various combinations.
. Results
.1. Comparison of viral RNA isolation techniques
To investigate the optimal RNA isolation protocol for high-
hroughput HIV-1 sequencing, a total of 125 plasma or serum
amples were processed in ﬁve pilot experiments. The number of
linical samples used in each pilot ranged from 12 to 45, and the
iral loads varied from low (±12,000 copies/ml) to high (1–3 × 106
opies/ml). Three automated extraction systems with correspond-
ng isolation kits from different suppliers were used; all reagents
nd machines are commercially available. In addition, manual
xtractions were performed with the QIAamp Viral RNA Mini Kit.
he results of the pilot experiments are summarized in Table 1.
o be able to reconstruct near-complete HIV-1 genomes, it is nec-
ssary that all four RT-PCR amplicons are ampliﬁed. The number
f successfully ampliﬁed amplicons from manually puriﬁed RNA
solations was greater than that from all robotically isolated RNAPlease cite this article in press as: Cornelissen, M.,  et al., From clinical sa
of HIV-1 RNA for high-throughput deep sequencing. Virus Res. (2016)
reparations. For RNA isolated with the m2000sp and MagNa Pure
ystems, more than two RT-PCR amplicons could be generated only
arely, precluding complete HIV-1 genome sequencing. The best
obotic RNA isolation method used the QIAamp Viral RNA Kit ingenerated 0–2, 3, or 4 HIV-1 amplicons is provided per ﬁve-year sampling period
(three year period for the most recent category from 2010 to 2012), ranging from
1985 to 2012.
combination with the automated QIAcube system. Based on these
results, it was  decided to use manual extraction with the QIAamp
Viral RNA Kit as the method of choice for the BEEHIVE study,
notwithstanding the additional time and staff required.
3.2. Sample characteristics and HIV-1 complete genome
sequencing
In ﬁve subsequent experiments, HIV-1 RNA was manually iso-
lated, ampliﬁed by RT-PCR and sequenced from a total of 616 Dutch
patient samples (Table 1). The robustness of the chosen isolation
method could thus be assessed, and sample characteristics asso-
ciated with RT-PCR performance were investigated. Most samples
(76.5%) contained subtype B viruses. The overall RT-PCR success
rate for the 616 samples, divided into ﬁve sets of 48–206 samples
each, for generating the four amplicons ranged between 48 and 89%
(mean 75%) (Fig. 1). The two  subsets that performed below 80% in
the ampliﬁcations contained 131 samples dating to the early years
of the HIV-1 epidemic in the Netherlands, i.e. from 1985 to 1994
(Fig. 2). Older samples are more likely to contain degraded viral RNA
due to storage conditions or multiple freeze-thaw cycles. In favourmple to complete genome: Comparing methods for the extraction
, http://dx.doi.org/10.1016/j.virusres.2016.08.004
of RNA degradation is the observation that the smallest amplicon
of 1.9 kb was  ampliﬁed for the majority of samples irrespective of
their age, while a lower success rate was scored for the three larger
amplicons (result not shown).
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Table 2
Overview of HIV RNA isolation methods for full-length genome sequencing from clinical specimens.
Reference Input patient material RNA isolation method (RT-)PCR strategy Sequencing platform and concluding
remarks
Gall et al., 2012 4 UK HIV-1 infected blood plasma
samples. Viral load range
3000–300,000 copies/ml
Manual RNA isolation with the QIAamp
Viral RNA Mini Kit
SuperScriptIII RT/
Platinum Taq High Fidelity. PCR
reactions amplify four fragments
454 Life Sciences/Roche platform. All
four fragments ampliﬁed, smallest
fragment of 1,9 kb gives the best
ampliﬁcation. For all samples, the
complete amino acid coding region of
the HIV-1 genome was covered
Henn et al., 2012 89 Blood plasma samples of 83 HIV-1
subtype B infected participants of
North American, Swiss and German
cohorts
Manual RNA isolation with the QIAamp
Viral RNA Mini Kit Pre-treatment:
plasma samples (1 ml)  were
centrifuged for 1 h at 20.817 g.
Superscript III RT (Invitrogen)
PCR reactions amplify four fragments
of 3.2 kb each
454 Life Sciences/Roche platform. Only
a few samples failed to amplify all four
fragments with subsequent low
sequence coverage
Giallonardo et al., 2014 2 Clinical samples (1 ml  plasma) from a
Swiss HIV-1 cohort
Manually with the NucleoSpin RNA
Virus Kit (Macherey and Nagel,
Oensingen)
Pre-treatment: plasma samples (1 ml)
were centrifuged for 1 h at 50.000 g.
PrimeScript Reverse Transcriptase
(Clontech). Nested or semi-nested PCR
amplifying 5 and 11amplicons,
respectively
Illumina MiSeq instrument as well as
the Paciﬁc Biosciences platform
Berg et al., 2016 8 HIV-1 infected blood plasma samples
from blood banks in Cameroon, South
Africa and Thailand. For the m2000sp
extraction 500–600 l of sample was
used
RNA isolation with the RNA Sample
Preparation System (Abbott Molecular;
Des Plaines, IL) on a m2000sp
instrument. Extractions were also
performed using the MagMax (Life
Technologies: Grand Island, NY), Viral
Mini (Qiagen), Ultra Sens Virus
(Qiagen), and PureLink (Life
Technologies) kits with or without
automated extractions
SMARTScribe Reverse Transcriptase
(Clontech, Mountain View, CA).
Subsequent ampliﬁcation with a
mixture containing 6 HIV speciﬁc
primers
Illumina MiSeq instrument. All 8
clinical samples achieved between
95–100% genome coverage with
average sequence depths ranging from
494× to 6481×
Brener et al., 2015 Transmission pair: 3 samples from
donor and 3 from recipient. pVL range
from 3000 to ±80,000 copies/ml.
Manual RNA isolation with the QIAamp
Viral RNA Mini Kit. Pre-treatment:
plasma samples (1 ml)  were
centrifuged for 1 h at 21.000 rpm. For
samples with a pVL <3000 copies/ml
3  ml  input volume was used
Superscript III One-Step RT-PCR with
Platinum Taq High Fidelity
Enzyme Mix  (Invitrogen, Carlsbad,
California, US).
Illumina MiSeq 250 bp paired end
technology
Luk et al., 2015 35 Blood plasma samples. Specimens
with high viral loads ranging from 4.45
to 5.90 log10 copies/mL were selected.
EZ1 Virus Mini Kit v2.0 protocol for
Serum (Qiagen) with the EZ1 BioRobot
robotic extraction
MMLV  SuperScript III Reverse
Transcriptase (Invitrogen/Life
Technologies, Carlsbad, CA), using a
primer that has a random 9-mer linked
to a speciﬁc 17-mer sequence
Illumina MiSeq instrument. Greater
than 90% genome coverage achieved
for 31 (89%) of the 35 specimens,
average sequence depth ranging from
37- to 8274-fold, permitting full length
viral genome assembly for 25 (71%)
Ode et al., 2015 97 Blood plasma samples obtained
from 58 Japanese patients were used.
The plasma viral load ranged from
10–28,000 copies/ml
RNA extracted from 200 or 400 l
plasma with the MagNAPure Compact
Nucleic Acid Isolation Kit I (Roche
Diagnostics) and MagNA Pure Compact
Instrument
RT reaction with PrimeScript II High
Fidelity One Step RT-PCR Kit (Takara,
Shiga, Japan).
HIV-1 nucleotides 706-8825 (gag-nef)
were ampliﬁed in four nested
overlapping fragments
Illumina MiSeq instrument. The four
segments were successfully ampliﬁed
for the subtype B samples with >200
copies/ml. Of the 39 non-B subtype
viruses, subtype F often failed in
int-env fragment ampliﬁcation
Zanini et al., 2015 9 Swedish HIV-1 infected patients,
7–12 blood plasma samples each,
resulting in a total of 73 clinical
samples. Samples dated to 1990–2003
and had always been stored at −70 ◦C.
Plasma viral load range 0–648,000
copies/ml
Manual extraction with RNeasy Lipid
Tissue Mini Kit (Qiagen)
Superscript III One-Step RT-PCR with
Platinum Taq High Fidelity
Enzyme Mix  (Invitrogen, Carlsbad,
California, US). Subsequent PCR
ampliﬁcation of six overlapping
fragments, nt. 571-9567 of HXB2
reference strain
Illumina MiSeq instrument. One
fragment had a signiﬁcantly lower
coverage than the other ﬁve. Lower
viral loads generally resulted in less
coverage
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Rig. 3. RT-PCR success rate and plasma viral load. The percentage of BEEHIVE sam-
les that generated 0–2, 3, or 4 HIV-1 amplicons was calculated for ﬁve HIV-1 plasma
iral load groups plus the samples with unknown viral load.
The initial viral load in the samples is another important fac-
or for RT-PCR success rates, with lower viral loads expected to
orrelate with RT-PCR failure. Fig. 3 indicates that the success rate
or amplifying all four amplicons was much lower for samples with
ower viral loads ≤5000 copies/ml (34%) than for samples with high
iral loads >100,000 copies/ml (86%). For samples with intermedi-
te viral loads between 5000 and 100,000 copies/ml, the success
ate was 65%.
Viral load was, similar to sample age, not a major factor in suc-
essful ampliﬁcation of the shorter, 1.9 kb, amplicon, which could
e ampliﬁed for 451/616 samples (73%). Individual success rates
or the three larger amplicons were 65%, 62% and 64%, respectively.
.3. HIV-1 RNA isolation methods used in other studies
A literature search for methods used to isolate HIV-1 RNA for
omplete genome high-throughput sequencing was performed. A
otal of eight publications were retrieved and inspected for the sam-
le type involved, the RNA isolation method used and the outcomes
f the sequencing protocol. The results are summarized in Table 2.
ll eight studies concerned blood plasma samples, none reported
he use of serum. Numbers of samples analysed ranged from one
o 97. Table 2 illustrates that the studies differed greatly in the
eporting of details of the samples the actual results of sequenc-
ng. Only ﬁve publications provided the viral load of the samples,
r more speciﬁcally, the input RNA copy numbers for the RT-PCR
mpliﬁcation. Two studies reported the use of machines for RNA
solation (Luk et al., 2015; Ode et al., 2015), one study apparently
lternated between machine and manual extraction (Berg et al.,
016), while the remaining ﬁve studies exclusively used manual
xtraction (Brener et al., 2015; Gall et al., 2012; Giallonardo et al.,
014; Henn et al., 2012; Zanini et al., 2015).
. Discussion
A total of 125 plasma samples from HIV-1-positive individu-
ls, intended for high-throughput complete genome sequencing,
ere subjected to three different viral RNA isolation methods, the
IAamp Viral RNA Mini Kit (Qiagen), the mSample Preparation Sys-Please cite this article in press as: Cornelissen, M.,  et al., From clinical sa
of HIV-1 RNA for high-throughput deep sequencing. Virus Res. (2016)
ems RNA Kit (Abbott Molecular), and the MagNA Pure 96 System
Roche Diagnostics). The latter two isolation kits are to be used
ith a machine developed by the supplier, while the QIAamp Viral
NA Mini Kit can either be used for manual RNA isolation or with PRESS
arch xxx (2016) xxx–xxx
a matching robotic system. Subsequently, isolated viral RNA was
reverse-transcribed and used for the ampliﬁcation of four over-
lapping RT-PCR amplicons that span almost the complete HIV-1
genome. Generation of all four amplicons is essential for successful
sequencing of the near-complete viral genome. Isolating sufﬁcient
virus genome RNA molecules of sufﬁcient length is an important
factor in generating these RT-PCR amplicons, the second factor
being the speciﬁc primer sets used. In earlier tests, the pan-HIV-1
primer sets employed here were used for successful ampliﬁcation
of HIV-1 group M,  N, and O sequences, including all major group M
subtypes and many circulating recombinant forms, either from cell
culture reference viruses, primary clinical isolates and uncultured
plasma virus samples (Gall et al., 2012). Therefore, we  assumed that
failure to amplify an HIV-1 amplicon in this pilot study is mainly
due to insufﬁcient quantity and/or quality of the isolated viral RNA,
and less so due to non-matching RT-PCR primers. We  conclude
that generation of the complete set of four amplicons has the high-
est success rate when the QIAamp Viral RNA Kit is combined with
manual RNA extraction. This isolation method also worked compar-
atively well with machine extraction, suggesting that the QIAamp
Viral RNA Kit outperforms the isolation methods from other sup-
pliers. The outcome may  suggest that manual HIV-1RNA isolation
results in less shearing of the 9 kb genome than robotic extractions.
Next, we  used the optimal isolation method for 616 plasma sam-
ples from HIV-1-positive patients included in the BEEHIVE study
to assess what sample characteristics inﬂuence the reverse tran-
scription and/or the ampliﬁcation process. We report that both
sample age and plasma viral load inﬂuence the RT-PCR success.
The smallest amplicon of 1.9 kb was ampliﬁed for 73.2% of the sam-
ples, whereas the larger amplicons (>3 kb) exhibit reduced success
rates between 61.9 and 65.1%. The observation that ampliﬁcation
results correlate with amplicon length suggests that differences in
the number of intact RNA copies is more important than primer
mismatches with the target sequence. A low input RNA concentra-
tion in the RT-PCR reaction is most likely due a low sample viral load
or because of RNA degradation related to sample age, suboptimal
storage and/or multiple freeze-thaw cycles.
Analysis of the literature indicated that a wealth of RNA isolation
systems are used by others. As RT-PCR approaches differ and report-
ing of sequencing success was incomplete and not uniform, it is
difﬁcult to estimate the relative value of each RNA isolation method.
Each study deﬁnes its own  endpoint; for instance, the sequence
coverage per position in the HIV-1 genome is not standardised as
to what cut-off should be used for reliable assembly. Viral load is
an important factor determining sequence success. However, for a
number of samples with low viral loads sufﬁcient sequence infor-
mation was generated, while for some samples with high viral
loads ampliﬁcation steps failed, suggesting that a combination of
RNA input and speciﬁc primers was more important than either
of these factors alone. No study generated full-length sequences of
the HIV-1 RNA genome. Due to the position of the RT-PCR primers,
the complete long terminal repeats (LTR) are lacking in the study of
Ode et al. (2015), while in the other seven studies at least part of the
LTRs are missing. The actual length of the “complete” genome thus
differs between studies, although all approaches cover the entire
protein-coding region. Manual extraction was  done in ﬁve out of
eight studies, two others reported machine isolation only, while an
eighth study used a plethora of isolation methods. Manual extrac-
tion obviates the need for a machine, but it can be labour-intensive
and slow when dealing with a large numbers of samples. From the
present study we  conclude that manual RNA isolation results in a
better RNA quality necessary for complete HIV-1 genome sequenc-mple to complete genome: Comparing methods for the extraction
, http://dx.doi.org/10.1016/j.virusres.2016.08.004
ing and that shorter amplicons are more successful for sequencing
directly from clinical samples.
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. Conclusions
Manual isolation of HIV-1 RNA from plasma with the QIAamp
iral RNA Mini Kit yields the best results when analysing the
umber of amplicons generated in subsequent RT-PCR reactions
or complete genome high-throughput sequencing, compared
ith either machine RNA isolation using the same kit or other
it/machine combinations from different suppliers. High sample
ge and low initial plasma viral load were found to negatively inﬂu-
nce the ampliﬁcation of HIV-1 fragments >3 kb.
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